Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,733.68
(
0.51%
)
US TECH 100
24,200.40
(
0.77%
)
Dow Jones
47,182.94
(
0.50%
)
Brent Oil
99.33
(
1.04%
)
Bitcoin
74,220.21
(
-0.83%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 112927

Monday, 07/11/2011 4:41:46 PM

Monday, July 11, 2011 4:41:46 PM

Post# of 257251
Orencia outsells Rituxan 2:1 in US RA market, according to Decision Resources:

http://finance.yahoo.com/news/BristolMyers-Squibbs-Orencia-bw-989819946.html?x=0&.v=1

These drugs are competitors for the non-TNF-a segment of the RA market, usually in the third-line setting (following methotrexate in the first line and one of the TNF-a drugs in the second line). Roche’s Actemra is a distant third to Orencia and Rituxan in this market segment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now